Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
5.67 USD
0.89%
Market Closed
Updated:
May 6, 2024
Editas Medicine Inc
Cash from Financing Activities
|
Editas Medicine Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Cash from Financing Activities
$118m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Editas Medicine Inc's Cash from Financing Activities?
Cash from Financing Activities
118m
USD
118m
USD
Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Cash from Financing Activities amounts to 118m USD.
What is Editas Medicine Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
6%
6%
Over the last year, the Cash from Financing Activities growth was 9 122%. The average annual Cash from Financing Activities growth rates for Editas Medicine Inc have been -19% over the past three years , 6% over the past five years .
You don't have any saved screeners yet
